Ann Coloproctol > Volume 38(2); 2022 > Article |
|
Marker | Year | Main outcome | Study | N | Design, center | Surgical disease | TNM stage | Cut-off | Therapy | Statistics and comments |
---|---|---|---|---|---|---|---|---|---|---|
NLR | 2020 | Postoperative complications OS DFS | Xia et al. [37] | 154 | Retrospective, single center | RC | T1–2 | 2.8 | Resection | NLR was associated with postoperative CTx. |
NLR was an independent prognostic factor for DFS (HR, 6.656, P = 0.009). | ||||||||||
NLR | 2019 | Ileostomy amount: 2,000 mL/day | Hiramoto et al. [43] | 45 | Retrospective, single center | CRC | 1–4 | 3.0 | Resection | Preoperative NLR was significantly higher in the high-output ileostomy group (P = 0.004). |
NLR | 2019 | OS DFS | Kim et al. [48] | 83 | Retrospective, 2 centers | CRLM | 4 | 1.94 | Resection, CTx | HR, 2.23; independent prognostic factor |
NLR | 2019 | pCR OS | Mao et al. [49] | 183 | Retrospective, single center | CRLM | 4 | 2.3 | Preoperative CTx, resection | OR, 2.40; P = 0.015 |
RFS | HR, 2.43; P < 0.001 | |||||||||
HR, 1.53; P = 0.017 | ||||||||||
NLR | 2019 | OS PFS | Casadei-Gardini et al. [51] | 276 | RCT, multi-center | mCRC | 4 | 3 | CTx (± bevacizumab) | HR, 2.38 |
HR, 2.27 | ||||||||||
NLR + LDH is a good prognostic marker for mCRC with 1st-line CTx. | ||||||||||
NLR | 2016 | OS | Ishizuka et al. [77] | 627 | Retrospective, single center | CRC | 1–4 | 2.9 | Resection | HR, 1.811; P = 0.003 |
NLR | 2016 | OS | Shibutani et al. [50] | 99 | Retrospective, single center | Unresectable mCRC | 4 | 3 | Palliative CTx | HR, 2.706; P = 0.001 |
NLR | 2016 | Tumor regression grade | Caputo et al. [42] | 151 | Retrospective, single center | RC | 2, 3 | 2.8 | nCRT followed by total mesorectal excision | Preoperative high NLR was associated with overall postoperative complications. |
Postoperative complications | ||||||||||
NLR | 2014 | pCR | Kim et al. [46] | 102 | Retrospective, single center | CRC | 1–4 | 3 | Preoperative CRT, resection | HR, 5.2; P = 0.04 |
CSS | HR, 6.6; P = 0.02 | |||||||||
RFS | HR, 2.8; P = 0.03 | |||||||||
NLR | 2014 | OS | Neofytou et al. [56] | 140 | Retrospective, single center | CRLM | 4 | 2.4 | Resection | NLR was not an independent prognostic factor for OS or DFS. |
DFS | ||||||||||
NLR | 2014 | Hospital LOS | Gohil et al. [41] | 196 | Retrospective, single center | CRC | 1–4 | 4.3 | Resection | Preoperative NLR was associated with increased LOS (OR, 1.702). |
NLR, neutrophil-lymphocyte ratio; OS, overall survival; DFS, disease-free survival; RC, rectal cancer; CTx, chemotherapy; HR, hazard ratio; CRC, colorectal cancer; CRLM, colorectal cancer with liver metastasis; pCR, pathologic complete response; RFS, relapse-free survival; OR, odds ratio; PFS, progression-free survival; RCT, randomized controlled trial; mCRC, metastatic colorectal cancer; LDH, lactate dehydrogenase; FOLFIRI, folinic acid, fluorouracil, and irinotecan; nCRT, neoadjuvant chemoradiotherapy; CSS, cancer-specific survival; LOS, length of stay.
Marker | Year | Main outcome | Author | N | Design, center | Surgical disease | TNM stage | Cut-off | Therapy | Statistics and comments |
---|---|---|---|---|---|---|---|---|---|---|
PLT | 2018 | pCR | Belluco et al. [35] | 965 | Retrospective, multicenter | RC with nCRT | 2, 3 | 300K | nCRT followed by TME | OR, 0.51; P=0.001 |
OS | HR, 1.45; P=0.009 | |||||||||
DFS | HR, 1.39; P=0.009 | |||||||||
PLT | 2012 | OS | Ishizuka et al. [36] | 453 | Retrospective, single center | CRC | 1–4 | 300K | Resection | OR, 1.642; P=0.039 |
Thrombocytosis is associated with OS. | ||||||||||
PLR | 2020 | Postoperative complication | Xia et al. [37] | 154 | Retrospective, single center | RC | T1–2 | 140.0 | Resection | PLR was associated with postoperative complications. However, PLR was not an independent prognostic factor for OS, DFS. |
OS | ||||||||||
DFS | ||||||||||
PLR | 2015 | CSS | Ozawa et al. [54] | 234 | Retrospective, single center | CRC | 2 | 25.4 | Resection | HR, 3.61; P=0.038 |
DFS | HR, 2.65; P=0.011 | |||||||||
PLR | 2014 | OS | Neofytou et al. [56] | 140 | Retrospective, single center | CRLM | 4 | 15 | Resection | HR, 2.17; P=0.027 |
DFS | HR, 1.68; P=0.034 |
PLT, platelet; OS, overall survival; DFS, disease-free survival; RC, rectal cancer; pCR, pathologic complete response; nCRT, neoadjuvant chemoradiotherapy; TME, total mesorectal excision; OR, odds ratio; HR, hazard ratio; CSS, cancer-specific survival; CRC, colorectal cancer; PLR, platelet-to-lymphocyte ratio; CRLM, colorectal cancer with liver metastasis.
Marker | Year | Main outcome | Author | N | Design, center | Surgical disease | TNM stage | Cut-off | Therapy | Statistics and comments |
---|---|---|---|---|---|---|---|---|---|---|
Alb | 2019 | OS | Yamamoto et al. [64] | 523 | Retrospective, single center | CRC | 1–4 | 3.85 | Resection | Kaplan-Meier test, P < 0.0001 |
DFS | ||||||||||
ΔAlba | 2018 | Postoperative complication | Wang et al. [63] | 193 | Retrospective, single center | CRC | 1–3 | 17.3% | Resection | OR, 1.66/+ |
Alb | 2017 | Postoperative morbidity, mortality | Chiang et al. [61] | 3,732 | Retrospective, single center | CC | 1–3 | 3.5 | Resection | OR, 0.927 |
OR, 0.844 | ||||||||||
Morbidity and mortality were inversely related to Alb. | ||||||||||
Alb | 2015 | 30-Day mortality | Montomoli et al. [62] | 9,339 | Prospective, population-based cohort | CRC | 1–4 | 2.5 | Resection | HR, 7.59 |
2.6–3.0 | HR, 5.19 | |||||||||
3.1–3.5 | HR, 2.58 | |||||||||
3.6–4.0 4.0 | HR, 1.75 | |||||||||
HR, 1.00 | ||||||||||
Preoperative Alb was inversely associated with 30-day mortality. | ||||||||||
Alb | 2014 | Hospital LOS | Gohil et al. [41] | 196 | Retrospective, single center | CRC | 1–4 | 34.5 g/dL | Resection | OR, 0.47/+ |
Alb | 2011 | Short-term outcomes | Lai et al. [65] | 3,849 | Retrospective, single center | CC | 1–3 | 3.5 | Resection | OR, 2.15; P < 0.001 |
OS | HR, 1.75; P < 0.001 | |||||||||
RFS | HR, 1.28; P = 0.020 | |||||||||
Alb | 2009 | OS | Sun et al. [66] | 1,367 | Retrospective, single center | CRC | 1–4 | 3.5 | Resection | HR, 1.45; P = 0.011 |
CSS | Alb was associated only with CSS. | |||||||||
CRP | 2017 | PFS | Artaç et al. [52] | 90 | Retrospective, 2 centers | mCRC | 4 | ULN | Bevacizumab + FOLFIRI | Only CRP was confirmed to be associated with PFS in the multivariate analysis. |
CRP | 2008 | CSS | Koike et al. [70] | 300 | Retrospective, single center | CRC | 1, 2 | 0.5 mg/dL | Resection | HR, 1.88/+ |
GPS | 2016 | OS | Ishizuka et al. [77] | 627 | Retrospective, single center | CRC | 1–4 | 0, 1, 2 | Resection | HR, 1.809; P = 0.006 |
mGPS | 2009 | Postoperative infection | Moyes et al. [76] | 455 | Retrospective, single center | CRC | 1–3 | 0, 1, 2 | Resection | HR, 1.76; P = 0.003 |
mGPS | 2007 | OS (3 yr) | McMillan et al. [74] | 316 | Retrospective, single center | CRC | 1–3 | 0, 1, 2 | Resection | Univariate analysis/+ |
CSS (3 yr) | ||||||||||
CAR | 2017 | Postoperative complication | Ge et al. [81] | 359 | Retrospective, single center | CRC | 1–3 | 0.022 | Resection | OR, 4.413; P < 0.001 |
CAR | 2017 | OS | Haruki et al. [84] | 112 | Retrospective, single center | CRLM | 4 | 0.04 | Resection | HR, 2.559; P = 0.021 |
DFS | HR, 1.731; P = 0.002 | |||||||||
CAR | 2017 | OS DFS | Ide et al. [83] | 115 | Retrospective, single center | RC with nCRT | 1–3 | 0.049 | nCRT followed by TME | HR, 5.09; P < 0.01 |
HR, 4.98; P < 0.01 | ||||||||||
CAR | 2016 | RFS | Shibutani et al. [85] | 705 | Retrospective, single center | CRC | 1–3 | 0.0271 | Resection | HR, 1.503/+ |
CSS | HR, 1.672/+ | |||||||||
CAR | 2016 | OS | Ishizuka et al. [77] | 627 | Retrospective, single center | CRC | 1–4 | 0.038 | Resection | HR, 2.613; P < 0.001 |
CAR | 2016 | OS | Shibutani et al. [50] | 99 | Retrospective, single center | Unresectable mCRC | 4 | 0.183 | Palliative CTx | HR, 1.866; P = 0.031 |
CAR | 2016 | Side effects (G3 or G4) | Tominaga et al. [82] | 136 | Retrospective, single center | CRC | 3 | 0.1 | Adjuvant CTx | HR, 7.06; P < 0.001 |
GAR | 2018 | OS | Hachiya et al. [87] | 941 | Retrospective, single center | CRC | 1–4 | 0.83 | Resection | HR, 1.979; P=0.001 |
NLR was also associated with OS. | ||||||||||
AGR | 2015 | OS | Shibutani et al. [88] | 66 | Retrospective, single center | Unresectable mCRC | 4 | 1.25 | CTx | HR, 2.247 |
PFS | HR, 2.662 | |||||||||
The high-AGR group showed superior chemotherapeutic response | ||||||||||
AGR | 2013 | OS | Azab et al. [89] | 534 | Retrospective, single center | CRC | 1–4 | < 1.029 | Resection, CTx | High AGR was associated with improved survival (HR, 0.25). |
1.028–1.321 | ||||||||||
> 1.321 | ||||||||||
LCR | 2020 | Postoperative complication (SSI) | Okugawa et al. [90] | 477 | Retrospective, 2 centers | CRC | 1–4 | 6,000 | Resection | Low LCR was associated with postoperative complication and survival. |
OS | ||||||||||
DFS |
Alb, albumin; OS, overall survival; DFS, disease-free survival; CRC, colorectal cancer; OR, odds ratio; CC, colon cancer; HR, hazard ratio; LOS, length of stay; RFS, relapse-free survival; CSS, cancer-specific survival; PFS, progression-free survival; mCRC, metastatic CRC; ULN, upper limit of normal; FOLFIRI, folinic acid, fluorouracil and irinotecan; CRP, C-reactive protein; GPS, Glasgow Prognostic Score; mGPS, modified GPS; CAR, CRP-albumin ratio; CRLM, colorectal cancer with liver metastasis; RC, rectal cancer; nCRT, neoadjuvant chemoradiotherapy; TME, total mesorectal excision; CTx, chemotherapy; GAR, globulin-albumin ration; AGR, albumin-globulin ration; SSI, surgical site infection; LCR, lymphocyte-CRP ratio.
Disease and serologic test | Short-term outcome | Overall survival | Disease-freesurvival | Progression-free survival |
---|---|---|---|---|
Colon cancer | ||||
CBC | ||||
Chemistry | Alb [61, 65] | Alb [65] | Alb [65] | |
Rectal cancer | ||||
CBC | NLR, PLR [37] | PLT [35] | NLR [37] | |
NLR [42] | PLT [35] | |||
Chemistry | CAR [83] | CAR [83] | ||
Colorectal cancer | ||||
CBC | NLR [41] | PLT [36], NLR [46] | NLR [46] | |
CAR [77] | ||||
Chemistry | Alb, NLR [41] | Alb [64] | Alb [64] | |
Alb [62, 63] | GPS [74] | LCR [90] | ||
mGPS [76] | CAR [77] | |||
LCR [90] | GAR [87] | |||
LCR [90] | ||||
Metastatic colorectal cancer | ||||
CBC | NLR [48-51] | NLR [48, 49] | NLR [51, 52] | |
PLR [56] | PLR [56] | |||
Chemistry | CAR [50] | CAR [84] | CRP [52] | |
CAR [84] | AGR [88] | |||
AGR [88] |
CBC, complete blood count; Alb, albumin; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; PLT, platelet; CAR, CRP-albumin ratio; mGPS, modified GPS; GPS, Glasgow Prognostic Score; GAR, globulin-albumin ration; LCR, lymphocyte-CRP ratio; AGR, albumin-globulin ration; CRP, C-reactive protein.
Resection of hepatic metastases from colorectal cancer.1992 August;8(2)